Omnipaque 300

contrast enhancement, Abdominal CT
Treatment
1 FDA approval
0 Active Studies for Omnipaque 300

What is Omnipaque 300

IohexolThe Generic name of this drug
Treatment SummaryIohexol is a type of medication used in medical imaging procedures. It helps make images more clear and is less toxic than other contrast agents. It is used for myelography, arthrography, nephroangiography, and arteriography.
Omnipaqueis the brand name
image of different drug pills on a surface
Omnipaque 300 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Omnipaque
Iohexol
2004
11

Approved as Treatment by the FDA

Iohexol, also known as Omnipaque, is approved by the FDA for 1 uses which include contrast enhancement .
contrast enhancement

Effectiveness

How Omnipaque 300 Affects PatientsIohexol is a safe and effective substance that can be used to help create images of body parts during medical procedures such as myelography or nephroangiography. It has low toxicity and is made up of non-ionic and water-soluble components, making it safer than other contrast agents.
How Omnipaque 300 works in the bodyOrganic iodine compounds work like an x-ray filter. When they are present in the body, they make certain structures easier to see on an x-ray. When these compounds are injected into the spinal canal, they make the subarachnoid spaces of the head and spine visible. When injected into the veins, they make the internal structures of the body more visible until the compound is diluted.

When to interrupt dosage

The proposed dosage of Omnipaque 300 is contingent upon the recognized condition. The amount of dosage is contingent upon the delivery method (e.g. Intravascular; Subarachnoid or Intra-articular; Intrathecal; Intravascular; Intravenous; Oral; Rectal) outlined in the following table.
Condition
Dosage
Administration
contrast enhancement
, 518.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 4500.0 mg, 300.0 mg/mL, 350.0 mg/mL, 240.0 mg/mL, 755.0 mg/mL, 9.0 mg/mL, 12.0 mg/mL, 647.1 mg/mL, 388.3 mg/mL, 647.0 mg/mL, 388.0 mg/mL
, Intravenous, Solution - Subarachnoid, Solution, Subarachnoid, Intravascular, Solution - Intravascular, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, For solution, Oral, For solution - Oral, Injection, solution, Solution - Oral, Solution - Intravenous, Intravenous; Subarachnoid, Liquid, Liquid - Intravenous, Liquid - Intravenous; Subarachnoid, Liquid - Subarachnoid, Injection, solution - Intrathecal; Oral; Rectal, Intravascular; Intravenous, Injection, solution - Intra-articular; Intrathecal; Intravascular; Intravenous; Oral; Rectal, Injection, solution - Intra-articular; Intravascular; Intravenous; Oral, Injection, solution - Intravascular; Intravenous, Intra-articular; Intrathecal; Intravascular; Intravenous; Oral; Rectal, Intrathecal; Oral; Rectal, Intra-articular; Intravascular; Intravenous; Oral, Injection, solution - Intravenous, Intrathecal; Intravascular; Intravenous; Oral, Intravascular; Intravenous; Oral, Injection, solution - Intravascular; Intravenous; Oral, Injection, solution - Intrathecal; Intravascular; Intravenous; Oral
Abdominal CT
, 518.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 4500.0 mg, 300.0 mg/mL, 350.0 mg/mL, 240.0 mg/mL, 755.0 mg/mL, 9.0 mg/mL, 12.0 mg/mL, 647.1 mg/mL, 388.3 mg/mL, 647.0 mg/mL, 388.0 mg/mL
, Intravenous, Solution - Subarachnoid, Solution, Subarachnoid, Intravascular, Solution - Intravascular, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, For solution, Oral, For solution - Oral, Injection, solution, Solution - Oral, Solution - Intravenous, Intravenous; Subarachnoid, Liquid, Liquid - Intravenous, Liquid - Intravenous; Subarachnoid, Liquid - Subarachnoid, Injection, solution - Intrathecal; Oral; Rectal, Intravascular; Intravenous, Injection, solution - Intra-articular; Intrathecal; Intravascular; Intravenous; Oral; Rectal, Injection, solution - Intra-articular; Intravascular; Intravenous; Oral, Injection, solution - Intravascular; Intravenous, Intra-articular; Intrathecal; Intravascular; Intravenous; Oral; Rectal, Intrathecal; Oral; Rectal, Intra-articular; Intravascular; Intravenous; Oral, Injection, solution - Intravenous, Intrathecal; Intravascular; Intravenous; Oral, Intravascular; Intravenous; Oral, Injection, solution - Intravascular; Intravenous; Oral, Injection, solution - Intrathecal; Intravascular; Intravenous; Oral

Warnings

Omnipaque 300 has two contraindications and must not be administered together with the conditions outlined in the following table.Omnipaque 300 Contraindications
Condition
Risk Level
Notes
Inadvertent intrathecal administration
Do Not Combine
parenteral administration
Do Not Combine
There are 20 known major drug interactions with Omnipaque 300.
Common Omnipaque 300 Drug Interactions
Drug Name
Risk Level
Description
7-Nitroindazole
Moderate
The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Iohexol.
Acetazolamide
Moderate
The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Iohexol.
Amifampridine
Moderate
The risk or severity of seizure can be increased when Iohexol is combined with Amifampridine.
Amobarbital
Moderate
The therapeutic efficacy of Amobarbital can be decreased when used in combination with Iohexol.
Barbexaclone
Moderate
The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Iohexol.
Omnipaque 300 Toxicity & Overdose RiskOverdosing on non-ionic contrast agents like iohexol can be damaging to the kidneys. Toxic effects can include cell death, energy failure, issues with calcium levels, and changes in the cells of the tubules. These effects are believed to be caused by oxidative stress.

Omnipaque 300 Novel Uses: Which Conditions Have a Clinical Trial Featuring Omnipaque 300?

At present, there are 0 active clinical trials assessing the potential of Omnipaque 300 for use in Abdominal CT scans.
Condition
Clinical Trials
Trial Phases
contrast enhancement
0 Actively Recruiting
Abdominal CT
0 Actively Recruiting

Omnipaque 300 Reviews: What are patients saying about Omnipaque 300?

4Patient Review
8/4/2015
Omnipaque 300 for Method of X-Raying the Spinal Canal Using Dye
I nearly vomited during the CT scan.
4Patient Review
4/16/2012
Omnipaque 300 for X-Rays Done for Diagnostic Purposes
4Patient Review
11/19/2012
Omnipaque 300 for CT Scan of the Brain
3.7Patient Review
6/29/2014
Omnipaque 300 for Examination of the Bile Ducts and Pancreas
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about omnipaque 300

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does OMNIPAQUE stay in your system?

"Most of the drug is excreted within the first 24 hours, with the highest concentration in the urine occurring in the first hour after administration. The drug is cleared mainly by the kidneys."

Answered by AI

What are the side effects of OMNIPAQUE 300?

"runny nose,, watery eyes

The symptoms of a stress headache are mild to moderate pain, including backache, neck ache, and stiffness. Nerve pain, nausea, vomiting, fever, hives, stomach upset or pain, a runny nose, and watery eyes are also common."

Answered by AI

What does OMNIPAQUE 300 do?

"Omnipaque 300 Iohexol injection is a contrast agent used to help diagnose or find problems in the brain, back, heart, head, blood vessels, stomach, joints, pancreas, bladder, reproductive tract, and other parts of the body."

Answered by AI

What is OMNIPAQUE used for?

"This medication is used before X-ray imaging tests (such as CT scans). It contains iodine and belongs to a class of drugs known as contrast media or dyes. It works by adding contrast to body parts and fluids in these imaging tests."

Answered by AI
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top